Articles that tag GHRS but are mainly about other companies.
FDA lifted clinical hold on GH001, Phase 2b met primary endpoint with significant placebo-adjusted MADRS reduction, global Phase 3 program expected to initiate in 2026, and positioned as potential practice-changing treatment for treatment-resistant depression.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
